NCT04141475终止不适用
Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- change of LVEF between before and after 12 weeks of treatment
研究概览
简要总结
The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adult age ≥ 18 years
- •patient with diagnosed type 2 diabetes (history of pathological hyperglycemia according to WHO and HbA1c standards >7% or ongoing treatment with oral antidiabetic agents).
- •Patients with stable cardiomyopathy (no hospitalization in cardiology in the month before inclusion) with a left ventricular ejection fraction (LVEF) <50%.
- •patient who has signed an informed consent form
- •For women of childbearing age: effective contraception followed for at least 3 months before the start of the study and agreeing to keep it for the duration of the study.
- •affiliation to a social security scheme.
排除标准
- •With a coronary event in the year before inclusion.
- •With symptoms of cardiac ischemia at inclusion.
- •Pregnant or breastfeeding woman
- •Severe renal insufficiency
- •Using antioxidant molecules in the 6 months prior to inclusion.
- •Using drugs that can activate PPARs (Fibrates, Telmisartan, Enalaprilat).
- •Using anti-inflammatory drugs.
- •Suffering from acute infectious diseases and inflammatory diseases.
- •Hypersensitivity or a history of hypersensitivity reaction to gadoteric acid, meglumine or any drug containing gadolinium.
- •Non-inclusion criteria related to MRI:
- •with an implanted vascular stent less than 6 weeks before the examination;
- •carrier of an implanted biomedical device deemed "not safe" or "unsafe" in the list: http://www.mrisafety.com/TheList_search.asp;
- •Beneficiary of an acquisition procedure that does not respect the conditions required by "conditional" use in a subject carrying an implanted biomedical material considered "conditional" in the list: http://www.mrisafety.com/TheList_search.asp;
- •carrier of a ferromagnetic intraocular or intracranial foreign body close to the nerve structures;
- •carrying biomedical equipment such as a cardiac, neural or sensory pacemaker (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained to perform MRI in these subjects;
结局指标
主要结局
change of LVEF between before and after 12 weeks of treatment
时间窗: 12 weeks
percentage of blood ejection before and after 12 weeks of treatment
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery DiseaseLeft Ventricular MassType 2 DiabetesCoronary Artery DiseaseNCT01877590Wuhan General Hospital of Guangzhou Military Command66
Unknown
不适用
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor MutationsPrediabetes (Insulin Resistance, Impaired Glucose Tolerance)Familiar Hypocalcuric HypercalcemiaHealthy VolunteersType 2 Diabetes MellitusType 1 Diabetes MellitusNCT02023489Medical University of Vienna90
Unknown
4 期
Lovaza Mechanisms of ActionModerate Hypertriglyceridemia.NCT01301794Brigham and Women's Hospital40
已完成
不适用
se of alpha lipoic acid as a complementary treatment for the control of diabetesType 2 diabetes mellitusNutritional, Metabolic, EndocrineISRCTN13159380ational Autonomous University of Mexico135
已完成
不适用
Lipid Biomarkers for Diabetic Heart DiseaseType II Diabetes MellitusDiabetes ComplicationsNCT01752842Washington University School of Medicine70